Canada markets closed

Appili Therapeutics Inc. (APLI.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.04000.0000 (0.00%)
At close: 02:14PM EDT
Full screen
Previous Close0.0400
Open0.0400
Bid0.0350 x N/A
Ask0.0400 x N/A
Day's Range0.0400 - 0.0400
52 Week Range0.0250 - 0.0800
Volume31,819
Avg. Volume204,100
Market Cap4.851M
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

    MOUNTAIN VIEW, Calif., April 02, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into a definitive arrangement agreement ("Arrangement Agreement") to acquire Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. Under the Arrangement Agree

  • GlobeNewswire

    Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

    Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical counter

  • GlobeNewswire

    Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks

    A review of Russian and English literature suggests that Appili’s biodefense program ATI-1701 may have a role in preventing tularemia in UkraineHALIFAX, Nova Scotia, March 12, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia. Appili’s D